Simulations Plus SLP Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Total Services | $9.66M+1.2% | $9.54M— | —— | —— | $8.95M+9.0% | |
| Total Software | $14.64M+64.8% | $8.88M— | —— | —— | $13.48M+25.8% | |
| Gross Profit by Business | ||||||
| Services | $3.16M-7.7% | $3.42M+25.9% | $2.72M-8.1% | $2.96M+32.6% | $2.23M+4.2% | |
| Software | $12.99M+73.8% | $7.47M+4.8% | $7.13M-29.3% | $10.08M-7.5% | $10.9M+34.9% | |
| Gross Margin by Business | ||||||
| Services | 33%-3.0pp | 36%+35.0pp | 1%-37.0pp | 38%+13.0pp | 25%-1.0pp | |
| Software | 89%+5.0pp | 84%— | —— | 80%-1.0pp | 81%+6.0pp | |
| Concentration risk, percentage by Business | ||||||
| Total Services | 100%0.0pp | 100%— | —— | —— | 100%0.0pp | |
| Total Software | 100%0.0pp | 100%— | —— | —— | 100%0.0pp | |
| Cost of Goods and Services Sold by Business | ||||||
| Services | $6.5M+6.2% | $6.12M+6.8% | $5.73M+19.6% | $4.79M-28.7% | $6.72M+10.7% | |
| Software | $1.65M+16.7% | $1.41M-25.2% | $1.89M-25.7% | $2.54M-1.8% | $2.59M-1.9% | |
| Goodwill, Acquired During Period by Business | ||||||
| Services | $0— | $0— | $0— | —— | —— | |
| Software | $0— | $0— | $0— | —— | —— | |
| Goodwill, Impairment Loss by Business | ||||||
| Services | $0— | $0-100% | $8.98M0.0% | $8.98M0.0% | $8.98M0.0% | |
| Software | $0— | $0-100% | $571K— | —— | —— | |
| Revenue by Product | ||||||
| Clinical Operations | $415K+38.3% | $300K— | —— | —— | $894K-46.9% | |
| Commercialization | $2.28M-18.4% | $2.79M— | —— | —— | $2.35M+16.5% | |
| Development | $18.86M+35.0% | $13.97M— | —— | —— | $16.85M+21.0% | |
| Discovery | $2.73M+101% | $1.36M— | —— | —— | $2.34M+79.6% | |
| Total cost of revenues by Product | ||||||
| Services | $6.5M+6.2% | $6.12M+6.8% | $5.73M+19.6% | $4.79M-28.7% | $6.72M+10.7% | |
| Software | $1.65M+16.7% | $1.41M-25.2% | $1.89M-25.7% | $2.54M-1.8% | $2.59M-1.9% | |
| Concentration risk, percentage by Product | ||||||
| Clinical Operations | 3%0.0pp | 3%— | —— | —— | 7%-9.0pp | |
| Commercialization | 23%-6.0pp | 29%— | —— | —— | 25%0.0pp | |
| Development | 155%+2.0pp | 153%— | —— | —— | 150%+3.0pp | |
| Discovery | 19%+4.0pp | 15%— | —— | —— | 17%+5.0pp | |
| Revenue by Geography | ||||||
| Americas | $16.58M+23.3% | $13.45M+6.9% | $12.58M-13.5% | $14.54M-9.7% | $16.11M+11.4% | |
| Asia Pacific | $1.76M-4.6% | $1.84M-3.9% | $1.92M-9.7% | $2.12M+40.1% | $1.51M-12.7% | |
| EMEA | $5.96M+90.0% | $3.14M+5.6% | $2.97M-19.7% | $3.7M-23.1% | $4.81M+76.7% | |
| Concentration risk, percentage by Geography | ||||||
| Americas | 68%-5.0pp | 73%— | —— | 71%-1.0pp | 72%-4.0pp | |
| Asia Pacific | 7%-3.0pp | 10%— | —— | 11%+4.0pp | 7%-3.0pp | |
| EMEA | 25%+8.0pp | 17%— | —— | 18%-3.0pp | 21%+7.0pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Simulations Plus break its business down?
- Simulations Plus (SLP) reports revenue by business across 2 parts — Total Services and Total Software. Each is extracted from the segment footnotes and tracked over time.
- Where does Simulations Plus's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Simulations Plus's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
